Windhover.com | Medtech Insight | The RPM Report | Inteleos | EBI
Subscriber Username:   Password: Forgot Password?
Health Care Business Intelligence, Analysis, Insight - Windhover
Search


Receive Windhover's unique market insight fast with our free alert service 'Windhover's Update', including the latest abstracts and summaries from:

• IN VIVO
• Start-Up
• The RPM Report
• Medtech Insight


Sign up now



NEW THIS YEAR!
Perfect your dealmaking skills and find the perfect partners, all at the same time!

The Biotechnology Industry Organization (BIO) and Windhover Conferences are proud to host the combined BIO-Windhover AND Pharmaceutical Strategic Outlook together! For the first time ever, ALL partnering, plenary sessions and networking events are open to attendees of both conferences. One city, one trip, TWO blockbuster conferences!

For more information, please go to www.biowindhoverpso.com the combined BIO-Windhover/Pharmaceutical Strategic Outlook partnering site.

Interested in sponsoring this event?  Click here.


The IN VIVO Blog

IN3 Europe + Investor Day
April 28-30, 2010 · Paris, France

IN3 East + Investor Day
June 9-11, 2010 · Boston, MA

Euro-Biotech Forum
June 28-30, 2010 · Paris, France

Interested in presenting at a Windhover conference?
Submit your idea here


Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications. . . [MORE] (IN VIVO)

Despite Advances, Regenerative Medicine Faces Funding Crisis
Stem-cell and regenerative medicine firms are scrambling to find business models to harness the field's nascent, rapidly evolving science. Companies deep into clinical trials are still looking for pharma partnerships. . . [MORE] (Start-Up)

The Future of Drug-Eluting Stents Part II: Biodegradable Platforms
The safety profile of drug eluting stents appears to be improving with second and third-generation designs that utilize thinner struts (which are believed to reduce vessel injury and turbulent blood flow) and minimize or eliminate the polymer coating. . . [MORE] (Medtech Insight)

Health Reform in the Balance: What It Means for Biopharma
The long road to enacting health reform appeared to be close to an end with final negotiations taking place in the White House. But the Senate race for Ted Kennedy's open seat in Massachusetts has put the bill, and pharma's hard-fought concessions, in the breach. . . [MORE] (The RPM Report)

Read more from the latest: IN VIVO, Start-Up, The RPM Report, Medtech Insight, "The Pink Sheet", "The Pink Sheet" DAILY, "The Rose Sheet", "The Tan Sheet", PharmAsia News, Pharmaceutical Approvals Monthly, and "The Gray Sheet".




Pharma Deals
  FDA Has Full Plate This Fall for Vaccines: More Than H1N1
  GSK Slides Away From Innovation
  The Billion Dollar REMS: Xenazine?
Device Deals
  Stroke Devices: Facing Challenges Head On
  Vascular Closure Devices at the Crossroads
  What New Her2 Tests Say about Personalized Medicine

Interested in subscribing? Click here.
Publications - Databases - Conferences - About Us - Contact Us - Help - The IN VIVO Blog - RSS Feeds - Company Profiles - Subscriber Login

Copyright © 2010, Windhover Information, Inc. An Elsevier company. All rights reserved.

Elsevier Business Intelligence